Levy Raphi sold $232K of DRTS
Levy Raphi (Chief Financial Officer) sold 17,873 shares of Alpha Tau Medical Ltd. (DRTS) at $13.00 ($0.23M total) on 2026-07-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
For traders, the actionable takeaway is the confirmed insider sale size and that it was executed under a 10b5-1 plan, which generally lowers informational content versus discretionary selling.
Market read
A disclosed insider sale in DRTS (about $232K) is unlikely to be a standalone catalyst, but it can marginally influence sentiment.
What to watch
The filing date (2026-07-06) lags the sale date (2026-07-02), so any market reaction may be delayed and should be interpreted cautiously.
Background
The article is an SEC Form 4 insider transaction: CFO Levy Raphi sold shares in an open-market transaction under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Alpha Tau Medical CFO Levy Raphi sold 17,873 shares on 2026-07-02 for about $232.4K under a pre-arranged 10b5-1 plan.
Likely limited near-term impact; any reaction should be modest and short-lived unless accompanied by other company-specific news.
Form 4 provides a concrete transaction and confirms a 10b5-1 plan, which typically reduces the signal of new negative information.
Market effects
No clear sector read-through; this is company-specific insider transaction data.
None indicated.
None indicated.
Counterpoint
Insider selling under a 10b5-1 plan can be purely mechanical (tax/portfolio rebalancing) and may not reflect views on near-term prospects.
Key entities
- issuerAlpha Tau Medical Ltd.
Company whose CFO filed the Form 4 insider sale disclosure.
- insiderLevy Raphi
Chief Financial Officer who sold 17,873 shares on 2026-07-02.
